| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03182673 Details | 2022-09-01 Interventional | 1 | 31 | Fluzoparib Poly(ADP-ribose… Neoplasms Solid Tumor | Sponsor R & D Strategy Adjustment - | |||
| NCT04320290 Details | 2022-08-31 Interventional | 4 | 0 | Antiviral Agent… Hepatitis Hepatitis A Hepatitis C Renal Insuffici… Kidney Failure | New Related Protocol to be submitted - | |||
| NCT01840046 Details | 2022-08-31 Interventional | 1/2 | 4 | Interleukin-2 Alopecia Alopecia Areata | - - | |||
| NCT04854889 Details | 2022-08-30 Interventional | 2 | 3 | Decitabine Anemia Anemia, Aplasti… Refractory Apla… | Not achieve the desired effect - | |||
| NCT04470622 Details | 2022-08-30 Interventional | 2 | 27 | Aprepitant COVID-19 | Study was terminated early by Heron, and was not terminated for safety reasons. Study was terminated early by Heron, and was not terminated for safety reasons. The data reported is only safety data generated from the study. | |||
| NCT00936832 2008-005959-19 Details | 2022-08-30 Interventional | 2 | 0 | Calcium Fluorouracil Irinotecan Leucovorin Levoleucovorin Sunitinib Rectal Neoplasm… Colorectal Canc… Metastatic Canc… | because the sunitinib showed futility in anotehr trial - | |||
| NCT00819221 2008-007680-17 Details | 2022-08-30 Interventional | 1 | 44 | Doxorubicin Liposomal doxor… Olaparib Neoplasms Solid Tumors | - - | |||
| NCT03483883 Details | 2022-08-26 Interventional | 1 | 6 | Avelumab Gemcitabine Metastatic sRCC | The study was terminated due to protracted accrual and limited patient engagement in the
setting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features
and/or intermediate/poor risk clinical features. - | |||
| NCT04746339 Details | 2022-08-25 Interventional | 4 | 411 | Apixaban COVID-19 Thrombosis Covid19 | Due to the decrease in COVID cases and in the recruitment rate, and DSMB orientation. - | |||
| NCT04528758 Details | 2022-08-24 Interventional | 1 | - | Rhodamine 6G Coronary Artery… | re-evaluation of radiotracer - | |||
| NCT03445000 2017-002063-17 Details | 2022-08-24 Interventional | 2 | [5 Refs] | 14 | Alectinib Carcinoma, Non-… Lung Neoplasms Non-small Cell … Non-small Cell … Non-small Cell … | Low recruitment rate - | ||
| NCT00669071 Details | 2022-08-23 Interventional | 4 | 56 | Fluocinolone Ac… Hydroquinone Tretinoin Melanosis Melasma | Enrollment closed - | |||
| NCT04139395 Details | 2022-08-22 Interventional | 3 | 0 | Citric Acid Gallium citrate Sodium Citrate Fever Fever of Unknow… | Not feasible at this time. - | |||
| NCT03778073 Details | 2022-08-22 Interventional | 1 | 18 | Antibodies, Mon… Bendamustine Hy… Lymphoma Lymphoma, B-Cel… B-cell Non Hodg… Richter's Trans… | Strategic/Business Decision - | |||
| NCT03422523 2016-002654-21 Details | 2022-08-22 Interventional | 2 | 53 | Atezolizumab Gemcitabine Oxaliplatin Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… Refractory Diff… Relapsed Diffus… | Failure to reach pre-specified futility boundary - | |||
| NCT03379051 Details | 2022-08-22 Interventional | 1/2 | 78 | Lenalidomide Venetoclax Leukemia, Lymph… Chronic Lymphoc… Non-Hodgkin Lym… | Strategic/Business Decision - | |||
| NCT01975272 Details | 2022-08-22 Interventional | 4 | 27 | Ferric Compound… Ferrous fumarat… Iron Anemia Postoperative A… | Disapointing randomization rate Evident conclusions cannot be drawn from this small prematurely stopped study. | |||
| NCT04360135 Details | 2022-08-18 Interventional | 2/3 | 0 | Acetaminophen Pain, Postopera… Post Operative … | The study was closed on 3/8/2021 as per final progress report issued by the IRB on 3/12/2021.
No subjects were enrolled in the study following approval. Status changed to "Withdrawn (No
Participants Enrolled)" accordingly. - | |||
| NCT03970382 Details | 2022-08-18 Interventional | 1 | 21 | Aldesleukin Interleukin-2 Nivolumab Neoplasms Solid Tumor | Business decision - | |||
| NCT02341625 2014-002485-70 Details | 2022-08-18 Interventional | 1/2 | 126 | Nivolumab Advanced Cancer | Study terminated for business reasons not related to safety. - |